Bio-Techne (TECH) Q1 2026: Cell Therapy Headwind Drives 400 bps Growth Drag, Margin Expansion Outpaces Peers
Bio-Techne’s Q1 was marked by a pronounced 400 basis point headwind from cell therapy customer order timing, yet management drove 90 basis points of margin expansion and signaled stabilization in academic and biotech end markets. Underlying momentum in core franchises and China offsets near-term lumpiness, with margin discipline positioning the company for a return to growth in the second half. Investors should watch for recovery in cell therapy demand and further acceleration in spatial biology and protein analytical tools as comps ease.
Summary
- Cell Therapy Volatility: Order timing from two major customers created a sharp, temporary drag on growth.
- Margin Discipline Holds: Cost management and productivity gains enabled sector-leading profitability despite revenue softness.
- Core Business Resilience: Stabilizing trends in academia, biotech, and China set the stage for a second-half rebound.
Performance Analysis
Bio-Techne’s Q1 saw a 1% organic revenue decline, with reported revenue at $286.6 million. The most significant drag came from the cell therapy business, where two large customers received FDA fast-track designations, accelerating their clinical timelines but sharply reducing near-term reagent orders. Excluding this timing dynamic, organic growth was positive at 1% for the quarter, and management expects a 400 basis point headwind from these customers in Q2 before this effect moderates in the second half.
Profitability was a standout, with adjusted operating margin expanding 90 basis points to 29.9%, driven by productivity initiatives and the divestiture of the exosome diagnostics business. Adjusted gross margin rose to 70.2%. The diagnostics and spatial biology segment, while down 4% on a reported basis due to divestitures, delivered 3% organic growth and saw operating margin more than double year-over-year. China posted its second consecutive quarter of growth, and core protein analytical tools and diagnostics franchises showed resilience, with consumables and instrument launches fueling momentum.
- Cell Therapy Timing Swing: Two major GMP protein customers’ order cycles led to a 200 basis point headwind in Q1, worsening to 400 basis points in Q2 before easing later in the year.
- Academic and Biotech Stabilization: U.S. academic demand improved as the quarter progressed, with Europe and China both returning to growth, and biotech funding showing early signs of recovery.
- Segment Divergence: Protein sciences declined 3% organically (excluding cell therapy, up 1%), while diagnostics and spatial biology grew 3% organically, lapping mid-teens growth comps from the prior year.
Despite top-line volatility, cost discipline and operational focus allowed Bio-Techne to protect margins and position for a return to growth as end markets recover and cell therapy headwinds fade.
Executive Commentary
"Despite these efforts, organic revenue declined 1% in the quarter, primarily due to clinical stage timing from a couple of large customers in our cell therapy business and the anticipated ongoing softness in biotech funding... Operationally, the team delivered sector-leading profitability with adjusted operating margin, expanding 90 basis points year-over-year to 29.9%, exceeding our initial expectations."
Kim Kelderman, President and Chief Executive Officer
"Our better-than-expected margin reflects deliberate management of productivity and cost containment measures aimed at maximizing operating leverage in a dynamic environment... We remain on track to achieve at least 100 basis points of margin expansion for the full fiscal year."
Jim Hippel, Chief Financial Officer
Strategic Positioning
1. Cell Therapy: Managing Clinical Stage Volatility
The cell therapy segment faced acute near-term headwinds as two major customers, following FDA fast-track designations, front-loaded reagent purchases last year and dramatically slowed orders as they advanced to late-stage trials. This “lumpiness” is a structural feature of the clinical pipeline, but Bio-Techne’s growing customer funnel—700 customers, 85 in clinical phases—positions it for long-term growth as more therapies approach commercialization. Management expects the headwind to fade in the second half, with a return to normalized demand as validation and manufacturing ramp up.
2. ProteinSimple and Analytical Tools: Platform Adoption Accelerates
ProteinSimple, proteomic analytical solutions, saw robust double-digit consumable pull-through and continued strong utilization across its installed base. The launch of the ultra-sensitive SimplePlex cartridge and the Leo high-throughput platform exceeded placement and revenue expectations, particularly with large pharma. Maurice Biologics, a QA/QC biologics instrument, notched its sixth consecutive quarter of growth, with onshoring trends in U.S. pharma manufacturing likely to drive further demand.
3. Diagnostics and Spatial Biology: Innovation and Menu Expansion
Spatial biology rebounded sequentially, with RNAscope and Comet multi-omic platforms gaining traction in both academic and biopharma settings. New launches like ProximityScope extend Bio-Techne’s leadership in spatial proteomics. Diagnostics grew mid-single digits, aided by new kits (Amplidex PML-RAGA) and expanded partnerships (Oxford Nanopore), with the ESL-1 breast cancer test benefiting from positive clinical data. Segment margin improvement was driven by portfolio mix and productivity gains.
4. Geographic Recovery: China and Europe Outperform
China delivered its second straight quarter of growth, with demand from CROs and CDMOs (contract research/manufacturing organizations) driving instrument and reagent sales. EMEA (Europe, Middle East, Africa) posted low single-digit growth, led by academia. The Americas lagged due to cell therapy timing and biotech softness, but stabilization signals are emerging.
5. Capital Allocation and M&A: Balance Sheet Strength
Operating cash flow was $27.6 million, down year-over-year due to tax timing, but leverage remains low and M&A is a top capital deployment priority. The pending acquisition of the remaining Wilson Wolf stake (currently 20% owned) is seen as strategic, with the GDACS bioreactor platform expected to drive future cell therapy manufacturing scale and margin expansion.
Key Considerations
This quarter’s results highlight the importance of understanding both the cyclicality of clinical-stage businesses and the structural resilience of core franchises. Bio-Techne’s ability to expand margins despite top-line headwinds underscores strong operational discipline, while product innovation and geographic diversification provide additional levers for growth as market conditions improve.
Key Considerations:
- Cell Therapy Pipeline Dynamics: Fast-track designations accelerate customer pipelines but introduce near-term order volatility; long-term opportunity remains intact as more programs approach commercialization.
- Margin Expansion Sustainability: Productivity initiatives and portfolio mix shifts drove margin gains; ability to sustain these as volumes recover will be critical.
- Academic and Biotech Funding Trends: Signs of stabilization and funding upticks in both sectors suggest a potential inflection, with shorter lags to demand than in prior cycles.
- Platform Innovation: New product launches in spatial biology and protein analysis are driving customer adoption and broadening addressable markets.
- China and Onshoring Tailwinds: Renewed growth in China and U.S. pharma manufacturing investments could provide incremental upside as global supply chains realign.
Risks
Bio-Techne remains exposed to clinical-stage customer concentration, particularly in cell therapy where a small number of programs can drive outsized volatility. Academic funding uncertainty, especially with potential U.S. government shutdowns, and continued biotech funding pressures could delay recovery. Promotional activity to support customer retention may pressure margins if competitive intensity rises. Management’s margin targets depend on continued cost discipline amid uncertain top-line trends.
Forward Outlook
For Q2 2026, Bio-Techne guided to:
- Organic growth consistent with Q1, with a 400 basis point headwind from cell therapy timing.
- Continued operating margin expansion, targeting at least 100 basis points for the full year.
For full-year 2026, management maintained guidance:
- Low single-digit organic revenue growth, with a return to positive growth in the second half as headwinds abate.
Management cited improving funding trends in biotech and academia, easier comps in H2, and ongoing margin discipline as key drivers of the outlook.
- Underlying business ex-cell therapy expected to accelerate to 3% growth in Q2.
- China, spatial biology, and protein analytical tools expected to lead segment recovery.
Takeaways
Bio-Techne’s Q1 demonstrated the volatility inherent in clinical-stage businesses, but also the company’s ability to execute on cost and innovation levers. Margin expansion outpaced most peers, and stabilization signals in core end markets point to a strengthening setup for the second half.
- Clinical Timing Headwind: Cell therapy order cycles will continue to create quarterly volatility, but the pipeline remains robust and diversified, supporting future growth.
- Margin Flexibility: Productivity actions and portfolio mix shifts enabled margin expansion even with revenue softness; sustaining this as revenue recovers will be a key watchpoint.
- Second Half Inflection: As comps ease and funding stabilizes, Bio-Techne is positioned for a return to positive growth, with new product launches and geographic recovery providing incremental upside.
Conclusion
Bio-Techne navigated a challenging Q1 with disciplined execution, delivering margin gains and setting the stage for a second-half recovery. Investors should monitor the pace of cell therapy normalization, academic and biotech funding trends, and the impact of new product launches on segment growth.
Industry Read-Through
The volatility in cell therapy reagent demand underscores a broader challenge for life science tools companies with clinical-stage exposure, as order timing can swing quarterly results even when long-term trends are positive. Signs of stabilization in academic and biotech funding may signal a bottoming for the sector, with China’s renewed growth and U.S. onshoring activity providing tailwinds for instrument and reagent demand. Companies with diversified end markets, operational flexibility, and strong innovation pipelines are best positioned to outperform as the industry transitions from cyclical trough to recovery.